(c) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of their salts, (1)
3,4-methylenedioxy amphetamine. 5-methoxy-3,4-methylenedioxy amphetamine. 3,4,5-trimethoxy amphetamine. Bufotenine. Diethyltryptamine. Dimethyltryptamine. 4-methyl-2,5-dimethoxyamphetamine. Lysergic acid diethylamide. N-ethyl-3-piperidyl benzilate. N-methyl-3-piperidyl benzilate. Psilocybin.Tetrahydrocannabinols, except for tetrahydrocannabinols in hemp (as defined under section 1639o of title 7).
4-methylmethcathinone (Mephedrone). 3,4-methylenedioxypyrovalerone (MDPV). 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E). 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C–D). 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C). 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I). 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–2). 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–4). 2-(2,5-Dimethoxyphenyl)ethanamine (2C–H). 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C–N). 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C–P).Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of cannabimimetic agents, or which contains their salts, (2) In paragraph (1):
(A) The term “cannabimimetic agents” means any substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays within any of the following structural classes:
2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent.
3-(1-naphthoyl)indole or 3-(1-naphthylmethane)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent.
3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to any extent.
1-(1-naphthylmethylene)indene by substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent.
3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent.
(B) Such term includes— 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP–47,497);5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP–47,497 C8-homolog);
1-pentyl-3-(1-naphthoyl)indole (JWH–018 and AM678); 1-butyl-3-(1-naphthoyl)indole (JWH–073); 1-hexyl-3-(1-naphthoyl)indole (JWH–019); 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH–200); 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH–250); 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH–081); 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH–122); 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH–398); 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201); 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR–19 and RCS–4); 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR–18 and RCS–8); and 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH–203). Schedule II(a) Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate.Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in clause (1), except that these substances shall not include the isoquinoline alkaloids of opium.
coca [3] leaves, except coca leaves and extracts of coca leaves from which cocaine, ecgonine, and derivatives of ecgonine or their salts have been removed; cocaine, its salts, optical and geometric (b) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their (1)
Alphaprodine. Anileridine. Bezitramide. Dihydrocodeine. Diphenoxylate. Isomethadone. Levomethorphan. Levorphanol. Metazocine. Methadone-Intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl butane. Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid. Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine. Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate. Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid. Phenazocine. Piminodine. Racemethorphan. Racemorphan.Unless specifically excepted or unless listed in another schedule, any injectable liquid which contains any quantity of methamphetamine, including its salts, Schedule III
(a) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system:
Amphetamine, its salts, optical (2) Phenmetrazine and its salts.Any substance (except an injectable liquid) which contains any quantity of methamphetamine, including its salts, (4)
Methylphenidate.(b) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:
Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid.
Chorhexadol. [4] Glutethimide. Lysergic acid. Lysergic acid amide. Methyprylon. Phencyclidine. Sulfondiethylmethane. Sulfonethylmethane. Sulfonmethane. Nalorphine.(d) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof:
Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium.
Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts.
Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium.
Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(e) Anabolic steroids. Chloral betaine. Chloral hydrate. Ethchlorvynol. Ethinamate. Methohexital. Meprobamate. Methylphenobarbital. Paraldehyde. Petrichloral. Phenobarbital. Schedule VAny compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs, which shall include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:
Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams. Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams. Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams.Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.
Not more than 100 milligrams of opium per 100 milliliters or per 100 grams. Schedule IV[1] See Amendment of Schedules ofnote below.
[2] So in original. Probably should be “Alphacetylmethadol.”
[3] So in original. Probably should be capitalized.
[4] So in original. Probably should be “Chlorhexadol.”
2018—Subsec. (c). Pub. L. 115–334 inserted “, except for tetrahydrocannabinols in hemp (as defined under section 1639o of title 7)” after “Tetrahydrocannabinols” in schedule I(c)(17).
2012—Subsec. (c). Pub. L. 112–144, § 1152(b), added schedule I(c)(18) to (28).
1990—Subsec. (c). Pub. L. 101–647 added item (e) at end of schedule III.
1986—Subsec. (c). Pub. L. 99–646 amended schedule II(a)(4) generally. Prior to amendment, schedule II(a)(4) read as follows: “Coca leaves (except coca leaves and extracts of coca leaves from which cocaine, ecgonine, and derivatives of ecgonine or their salts have been removed); cocaine, its salts, optical and geometricPub. L. 99–570 amended schedule II(a)(4) generally. Prior to amendment, schedule II(a)(4) read as follows: “Coca leaves and any salt, compound, derivative, or preparation of coca leaves (including cocaine and ecgonine and their salts,Pub. L. 98–473, § 507(c), in schedule II(a)(4) added applicability to cocaine and ecgonine and their salts,Pub. L. 98–473, § 509(b), struck out subsec. (d) which related to authority of Attorney General to except stimulants or depressants containing active medicinal ingredients.
1978—Subsec. (d)(3). Pub. L. 95–633 added cl. (3).
Statutory Notes and Related Subsidiaries Effective Date of 1990 AmendmentAmendment by Pub. L. 101–647 effective 90 days after Nov. 29, 1990 , see section 1902(d) of Pub. L. 101–647, set out as a note under section 802 of this title.
Effective Date of 1978 AmendmentAmendment by Pub. L. 95–633 effective on date theJuly 15, 1980 ], see section 112 of Pub. L. 95–633, set out as an Effective Date note under section 801a of this title.
Amendment of Schedules of Controlled SubstancesPub. L. 106–172, §§ 2, 3(a), Feb. 18, 2000 , 114 Stat. 7, 8, provided that:
“SEC. 2. FINDINGS. “ Congress finds as follows:Gamma hydroxybutyric acid (also called G, Liquid X, Liquid Ecstasy, Grievous Bodily Harm, Georgia Home Boy, Scoop) has become a significant and growing problem in law enforcement. At least 20 “(2)
A behavioral depressant and a hypnotic, gamma hydroxybutyric acid (‘GHB’) is being used in conjunction with alcohol and other “(3)
GHB takes the same path as alcohol, processes via alcohol dehydrogenase, and its symptoms at high levels of intake and as impact builds are comparable to alcohol ingestion/intoxication. Thus, aggression and violence can be expected in some individuals who use such “(4)
If taken for human consumption, common industrial chemicals such as gamma butyrolactone and 1.4-butanediol are swiftly converted by the body into GHB. Illicit use of these and other GHB analogues and precursor chemicals is a significant and growing law enforcement problem.
A human pharmaceutical formulation of gamma hydroxybutyric acid is being developed as a treatment for cataplexy, a serious and debilitating disease. Cataplexy, which causes sudden and total loss of muscle “(6)
Abuse of illicit GHB is an imminent hazard to public safety that requires immediate regulatory action under the Controlled Substances Act (21 U.S.C. 801 et seq.).
“SEC. 3. EMERGENCY SCHEDULING OF GAMMA HYDROXYBUTYRIC ACID AND LISTING OF GAMMA BUTYROLACTONE AS LIST I CHEMICAL.
“(a) Emergency Scheduling of GHB.—“(1) In general.— The Congress finds that the abuse of illicit gamma hydroxybutyric acid is an imminent hazard to the public safety. Accordingly, the Attorney General, notwithstanding sections 201(a), 201(b), 201(c), and 202 of the Controlled Substances Act [21 U.S.C. 811(a)–(c), 812], shall issue, not later than 60 days after the date of the enactment of this Act [ Feb. 18, 2000 ], a final order that schedules suchControlled Substances Act as would apply to a scheduling of a substance by the Attorney General under section 201(h)(1) of such Act (relating to imminent hazards to the public safety), except as follows:
In the case of gamma hydroxybutyric acid that is contained in a Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355] (whether the application involved is approved before, on, or after the date of the enactment of this Act [ Feb. 18, 2000 ]), the final order shall schedule suchMay 19, 1999 .
“(2) Failure to issue order.—If the final order is not issued within the period specified in paragraph (1), gamma hydroxybutyric acid (together with its salts, Controlled Substances Act [21 U.S.C. 812(c)] in accordance with the policies described in paragraph (1), as if the Attorney General had issued a final order in accordance with such paragraph.”
Placement of Pipradrol and SPA in Schedule IV To Carry Out Obligation Under Convention on Psychotropic Substances